This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sealed Air (SEE) Earnings and Sales Surpass Estimates in Q4
by Zacks Equity Research
Sealed Air's (SEE) fourth-quarter earnings continues to benefit from its Reinvent SEE initiatives. Its 2021 adjusted earnings per share guidance suggests year-over-year growth of 4%.
Timken (TKR) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Timken (TKR) fourth-quarter earnings remained flat year over year as lower operating expenses on cost reduction actions are offset by lower volumes amid the pandemic.
AGCO Corp's (AGCO) Q4 Earnings & Sales Top Estimates, Up Y/Y
by Zacks Equity Research
AGCO Corp's (AGCO) Q4 results highlight sales growth and margin expansion across all segments.
Ball Corp (BLL) Q4 Earnings & Sales Top Estimates, Up Y/Y
by Zacks Equity Research
Ball Corp's (BLL) Q4 earnings rise year over year on increase in global beverage can volume growth.
Grainger (GWW) Q4 Earnings Lag, Revenues Beat Estimates
by Zacks Equity Research
Grainger's (GWW) fourth-quarter 2020 top-line results reflect share gains in the U.S. segment and stellar growth in the endless assortment businesses.
GPK vs. ATR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GPK vs. ATR: Which Stock Is the Better Value Option?
Avery Dennison (AVY) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Avery Dennison (AVY) reports year-over-year improvement in fourth-quarter 2020 earnings on cost saving initiatives and improving demand. It also expects to deliver improvement in fiscal 2021 results.
Honeywell (HON) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Honeywell's (HON) fourth-quarter 2020 revenues decline 6% year over year on account of lacklustre performance across Aerospace and Performance Materials and Technologies segments.
A. O. Smith (AOS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
A. O. Smith's (AOS) fourth-quarter 2020 net sales increase 11.1% year over year on solid performance across both of its segments.
Tetra Tech (TTEK) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Tetra Tech's (TTEK) first-quarter fiscal 2021 net revenues fall 1.5%, on account of weak performance of its Commercial / International Services Group segment.
Cimpress (CMPR) Q2 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Lackluster performance across its National Pen and Upload and Print segments hurts Cimpress (CMPR) second-quarter fiscal 2021 revenues.
3M's (MMM) Q4 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
3M's (MMM) fourth-quarter 2020 net sales increase 5.8% year over year on account of impressive performance across its segments.
Crane (CR) Q4 Earnings & Revenues Miss Estimates, Down Y/Y
by Zacks Equity Research
Crane's (CR) fourth-quarter 2020 net sales decrease 13.4% year over year largely due to the coronavirus outbreak-led issues, partially offset by positive impact from acquisitions and foreign exchange.
iRobot (IRBT) Gains From Solid Product Portfolio Amid Cost Woes
by Zacks Equity Research
iRobot (IRBT) benefits from its solid product portfolio, strong innovation capabilities and investments in building brand awareness. Pandemic-led uncertainties & high operating costs are concerns.
Berry Global (BERY) Displays Solid Prospects, Headwinds Persist
by Zacks Equity Research
Berry Global (BERY) stands to gain from strength across its end markets, acquired assets and strong cash flows. However, high costs and expenses along with huge debts pose concerns.
Here's Why AptarGroup (ATR) Stock is an Attractive Pick Now
by Zacks Equity Research
Demand for AptarGroup's (ATR) pharmaceutical products and sanitizers, liquid soaps and disinfectants makes the stock a prudent investment pick.
SON vs. ATR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SON vs. ATR: Which Stock Is the Better Value Option?
AptarGroup (ATR) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Triggered by the pandemic, increasing demand for pharmaceutical products and sanitizers, liquid soaps and disinfectants featuring AptarGroup's (ATR) solutions is driving its shares.
AptarGroup (ATR) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
AptarGroup (ATR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AptarGroup (ATR) Hits 52-Week High: What's Driving the Rally?
by Zacks Equity Research
Pandemic-induced demand for pharmaceutical products is likely to drive AptarGroup's (ATR) Pharma segment, while demand in personal care market and home care market will aid the Beauty + Home segment.
Here's Why You Should Hold On to AptarGroup (ATR) Stock Now
by Zacks Equity Research
Investors can retain AptarGroup (ATR) stock in their portfolio for the time being on upbeat prospects.
AptarGroup (ATR) Q3 Earnings & Sales Top Estimates, Shares Up
by Zacks Equity Research
AptarGroup's (ATR) top and bottom lines improve on solid growth in the Pharma segment as well as in the food, personal care and home care markets during the July-September period.
PKG vs. ATR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PKG vs. ATR: Which Stock Is the Better Value Option?
AptarGroup (ATR) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AptarGroup (ATR) delivered earnings and revenue surprises of 19.05% and 7.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
AptarGroup (ATR) Suffers From Weak End Markets Amid Pandemic
by Zacks Equity Research
AptarGroup's (ATR) third-quarter 2020 results are likely to reflect higher demand for pharmaceutical products amid the COVID-19 pandemic. However, weak beauty products sales will negate these gains.